Evidence map›Paper›PMID 40236956›Full record

ArticleBiomaterials research2025

Radiation-Activated Cobalt-Based Zeolite Imidazolate Frameworks for Tumor Multitherapy.

Qijun Du, Hongwei Jiang, Di Wu, Changlong Song, Wenqi Hu, Qinrui Lu, Chenwei Sun, Jie Liu, Guohua Wu, Shuqi Wang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Qijun DuClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Hongwei JiangLuoyang Key Laboratory of Clinical Multiomics and Translational Medicine, Henan Key Laboratory of Rare Diseases, Endocrinology and Metabolism Center, The First Affiliated Hospital, and College of Clinical Medicine, Henan University of Science and Technology, Luoyang 471003, China.
Di WuClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Changlong SongClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Wenqi HuClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Qinrui LuClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Chenwei SunClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Jie LiuClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Guohua WuClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.
Shuqi WangClinical Research Center for Respiratory Disease, West China Hospital, Sichuan University, Chengdu 610065, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radiation dynamic therapy (RDT) is known to induce cancer apoptosis and death with minimal side effects and high accuracy. However, low efficiency of radiation sensitization and persistent hypoxic environment in tumors pose marked challenges for successful RDT. To address these challenges, a novel biodegradable drug delivery system was developed, using quercetin and sorafenib-loaded ZIF67 nanoparticles (QSZP NPs) coated with polydopamine. This system effectively controlled the tumor microenvironment (TME), overcame hypoxia, and was thus utilized for collaborative RDT and radiotherapy (RT). The QSZP NPs demonstrated great potential in x-ray sensitization and reactive oxygen species (ROS)-mediated effects in vitro. Furthermore, they continuously generated oxygen and increased ROS levels in the TME with x-ray irradiation to achieve RDT. In vivo studies showed that QSZP NPs had no apparent systemic toxicity and showed good therapeutic effect in a HepG2 tumor-bearing model. Due to its unique and outstanding combinational effect of RDT/RT/antiangiogenic cancer therapy, these synthesized NPs offer a promising method for radiation-based cancer treatment.

Identifiers

PMID40236956
PMCPMC11997308

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.